<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03529201</url>
  </required_header>
  <id_info>
    <org_study_id>KE-0254/328/2017</org_study_id>
    <nct_id>NCT03529201</nct_id>
  </id_info>
  <brief_title>QLB After Nephrectomy</brief_title>
  <official_title>Effectiveness of Quadratus Lumborum Block After Nephrectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Lublin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Department of Anesthesiology and Intensive Care, F. Chopin Hospital in Rzeszów</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Department of Anesthesiology and Intensive Care, J. Śniadecki Hospital in Białystok</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of Lublin</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Oxycodone consumption and postoperative pain intensity in patients undergoing nephrectomy
      procedures. Of all study participants, 50% will obtain quadratus lumborum block (QLB).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients undergoing nephrectomy procedures will be allocated to one of the study arms. At the
      end of an operation, still under general anesthesia, 50% patients will obtain QLB with
      ropivacaine.

      Ultrasound-guided QLB will be performed on the side of surgery with 0.375% ropivacaine
      solution (0.2 mL per kg).

      Every patient will get patient-controlled analgesia pump with oxycodone in the postoperative
      period.

      Postoperative pain will be measured with VAS (visual-analogue scale) 2, 4, 8, 12 and 24 hours
      after the end of the operation. 24 -hours period.

      At the 1, 3, 6 months patients will be interviewed by phone to assess neuropathic pain.
      Neuropathic Pain Symptom Inventory (NPSI) will be used.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">May 7, 2018</start_date>
  <completion_date type="Anticipated">February 25, 2019</completion_date>
  <primary_completion_date type="Anticipated">September 28, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients will be randomly allocated to one of the study arms: QLB or control group.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>A regional block will be performed under general anesthesia. Patients will not be aware of this procedure.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Total consumption of oxycodone</measure>
    <time_frame>24 hours after the end of surgery.</time_frame>
    <description>Overall use of oxycodone administered by PCA pump will be assessed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain intensity</measure>
    <time_frame>24 hours after the end of surgery</time_frame>
    <description>Pain intensity measured on VAS scale at the 2, 4, 8, 12, 24 hours. VAS in milimmeters. Minimum value 0, maximum 100. Less better - less severe pain. 0 no pain at all.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic pain</measure>
    <time_frame>6 months after the surgery</time_frame>
    <description>Chronic pain occurrence assessed with Neuropathic Pain Symptom Inventory (NPSI) 10 descriptive variables, each one from 0 to 10. 0 means no pain. 10 very high chance of occurrence of neuropathic pain.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Pain, Postoperative</condition>
  <condition>Chronic Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>QLB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>At the end of surgery, QLB with ropivacaine will be done on the side of the operation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard care. No regional blocks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>QLB</intervention_name>
    <description>On the side of the surgery, QLB with 0.375% ropivacaine (0.2 mL/kg)</description>
    <arm_group_label>QLB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PCA</intervention_name>
    <description>Patient-controlled analgesia</description>
    <arm_group_label>QLB</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>GA</intervention_name>
    <description>General anesthesia</description>
    <arm_group_label>QLB</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone</intervention_name>
    <description>administered by PCA</description>
    <arm_group_label>QLB</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevoflurane</intervention_name>
    <description>Inhalational anesthetic during GA</description>
    <arm_group_label>QLB</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl</intervention_name>
    <description>painkiller during GA</description>
    <arm_group_label>QLB</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rocuronium</intervention_name>
    <description>muscle relaxant during GA</description>
    <arm_group_label>QLB</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  obtained consent

          -  nephrectomy procedure

        Exclusion Criteria:

          -  coagulopathy allergy to local anesthetics depression, antidepressant drugs treatment
             epilepsy usage of painkiller before surgery addiction to alcohol or recreational drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Michał Borys, M.D., Ph.D.</last_name>
    <phone>+48506350569</phone>
    <email>michalborys1@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mirosław Czuczwar, M.D., Ph.D.</last_name>
    <phone>+48509390985</phone>
    <email>czuczwarm@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Anesthesiology and Intensive Care, J. Śniadecki Hospital in Białystok</name>
      <address>
        <city>Białystok</city>
        <zip>15-950</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Piotr Gałkin, M.D.</last_name>
      <phone>+48601397139</phone>
      <email>piotr.galkin@anestezjolog.com.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Anesthesiology and Intensive Care, F. Chopin Hospital in Rzeszów</name>
      <address>
        <city>Rzeszów</city>
        <zip>35-055</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrycja Szajowska, M.D.</last_name>
      <phone>+48504068425</phone>
      <email>patrycjaguzek@poczta.onet.pl</email>
    </contact>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 1, 2018</study_first_submitted>
  <study_first_submitted_qc>May 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2018</study_first_posted>
  <last_update_submitted>May 17, 2018</last_update_submitted>
  <last_update_submitted_qc>May 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Lublin</investigator_affiliation>
    <investigator_full_name>Michał Borys</investigator_full_name>
    <investigator_title>M.D., Ph.D.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Oxycodone</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
    <mesh_term>Rocuronium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

